Balaxi Pharmaceuticals Ltd
BALAXI
Company Profile
Business description
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. Geographically it earns key revenue from Guatemala.
Contact
Phase-III, Road No: 81, Jubilee Hills
Plot No.409, H,No: 8-2-293
MAPS Towers, 3rd Floor
HyderabadTG500 096
INDT: +91 4023555300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
46
Stocks News & Analysis
stocks
Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown
We think Amazon stock looks attractive.
stocks
Apple earnings: Strong iPhone beat brings our valuation up and tariff costs prove light for now
We think Apple stock looks fairly valued.
stocks
4 ASX shares that could be vulnerable to an August surprise
Any missteps this reporting season could be costly for these shares, which have all risen to lofty valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,900.70 | 16.40 | -0.18% |
| CAC 40 | 7,546.16 | 225.81 | -2.91% |
| DAX 40 | 23,425.97 | 639.50 | -2.66% |
| Dow JONES (US) | 43,588.58 | 542.40 | -1.23% |
| FTSE 100 | 9,068.58 | 64.23 | -0.70% |
| HKSE | 24,507.81 | 265.52 | -1.07% |
| NASDAQ | 20,650.13 | 472.31 | -2.24% |
| Nikkei 225 | 39,949.12 | 850.48 | -2.08% |
| NZX 50 Index | 12,734.53 | 5.13 | 0.04% |
| S&P 500 | 6,238.01 | 101.38 | -1.60% |
| S&P/ASX 200 | 8,646.30 | 15.70 | -0.18% |
| SSE Composite Index | 3,559.95 | 13.26 | -0.37% |